X

Trial Profile

Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 02 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Garetosmab (Primary)
Indications Fibrodysplasia ossificans progressiva
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Regeneron Pharmaceuticals

Most Recent Events

25 Oct 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
09 Feb 2021 Planned End Date changed from 28 Feb 2022 to 8 Oct 2022.
09 Feb 2021 Planned primary completion date changed from 28 Aug 2021 to 1 Mar 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com